Dulaglutide
Also known as: Trulicity
Dulaglutide is a long-acting GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite.
This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.
- Drug class
- GLP-1 receptor agonist (Fc-fusion peptide)
- Primary targets
- GLP-1 receptor
- Dose reference
- FDA label (not a recommendation): 0.75 mg, 1.5 mg, 3 mg or 4.5 mg subcutaneously once weekly
- Half-life
- Approximately 5 days
- Developer / origin
- Eli Lilly
- Reference year
- 2014
- Evidence score
- 5/5 - Strong
Strong
Dulaglutide has robust, peer-reviewed primary evidence: the AWARD phase 3 program established dose-related glycemic efficacy, the REWIND randomized outcomes trial (9,901 participants, ~5.4 year median follow-up) demonstrated a reduction in major adverse cardiovascular events (HR 0.88), and an FDA label backs both diabetes and cardiovascular indications.
Approved medication with substantial human clinical evidence.
Evidence basis
- REWIND double-blind randomized placebo-controlled cardiovascular outcomes trial in The Lancet (2019), n=9,901
- AWARD-11 randomized controlled trial supporting expanded 3.0 mg and 4.5 mg doses in Diabetes Care (2021)
- FDA Trulicity prescribing information and DailyMed label with approved indications and pharmacokinetics
Key references
- The Lancet / PubMedDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- Diabetes Care / PMCEfficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg (AWARD-11)
- DailyMedTrulicity (dulaglutide) injection prescribing information
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Dulaglutide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Retatrutide
LY3437943
Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.
Tirzepatide
LY3298176, Mounjaro, Zepbound
Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.
Semaglutide
Ozempic, Wegovy, Rybelsus
Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.
Liraglutide
Victoza, Saxenda
Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.
Category hub
Open the category page for the full comparison table and FAQ.